Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545714 | 0.79 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL3278632 | 0.76 | — | — | |
| SCHEMBL14170465 | 0.73 | CCR2 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9187193 | 0.68 | PSEN1 (0.31) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4669859 | 0.66 | — | — | |
| SCHEMBL1720682 | 0.66 | — | — | |
| SCHEMBL4669725 | 0.66 | — | — | |
| SCHEMBL33526130 | 0.64 | — | — | |
| SCHEMBL6704381 | 0.63 | — | — | |
| SCHEMBL6060170 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539747-B1 | N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-20060040937-A1 | N-aroyl cyclic amines as orexin receptor antagonists | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1539747-A1 | N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004026866-A1 | N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-04-01 | — | — | WO | disclosed |
| EP-0361791-B1 | Azacyclic derivatives useful as medicaments | SMITHKLINE BEECHAM FARMA (IT) | 1995-11-08 | — | — | EP | disclosed |
| US-5089507-A | Also diuretic; long lasting, side effect reduction | DR. L. ZAMBELETTI SPA (IT) | 1992-02-18 | — | — | US | disclosed |
| EP-0447704-A1 | N-Acylated azacyclic compounds, processes for their preparations and their use as medications | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1991-09-25 | — | — | EP | disclosed |
| EP-0361791-A2 | Azacyclic derivatives useful as medicaments | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040937-A1 | N-aroyl cyclic amines as orexin receptor antagonists | HCRTR2, HCRTR1, NTSR2 | PSEN1 1307/4885PSEN2 1168/4885APH1B 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.